Page 93 - 2019_06-Haematologica-web

MK in EORTC/GIMEMA AML-10&12
MK+ patients. We found no evidence that the outcome was affected by the type of remission-induction chemotherapy. Donor availability was associated with prolonged survival among patients who reached a CR/CRi, suggesting a positive effect of allogeneic HSCT in this population of patients. These findings highlight the need for further prospective studies assessing the best strategy to bring MK+ patients to an allogeneic HSCT. In addition, efforts should be made to prevent post-trans- plant relapse and decrease transplant-related mortality in
MK+ AML patients. One possible strategy to do this could be post-transplantation prophylactic administration of hypomethylating agents, given their anti-leukemic activi- ty in MK+ patients27 and their ability to prevent graft-ver- sus-host disease.28
Funding
This publication was supported by a donation from the "Fondation Contre le Cancer" from "Belgium" through the EORTC Cancer Research Fund.
References
1. Willemze R, Suciu S, Meloni G, et al. High- dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC- GIMEMA AML-12 Trial. J Clin Oncol. 2014;32(3):219-228.
2. Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA groups study AML-10. J Clin Oncol. 2009;27(32):5397-5403.
3. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. J Clin Oncol. 2013;31(27):3360- 3368.
4. Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of
4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015;29(2):312- 320.
5. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommenda- tions from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
6. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
7. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analy- sis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102(4):1232-1240.
8. BreemsDA,vanPuttenWL,DeGreefGE,et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor progno-
sis than a complex karyotype. J Clin Oncol.
2008;26(29):4791-4797.
9. Cornelissen JJ, Versluis J, Passweg JR, et al.
Comparative therapeutic value of post- remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia. 2014;29(5):1041-1050.
10. Simons A, Shaffer LG, Hastings RJ. Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 edition. Cytogenet Genome Res. 2013;141(1):1-6.
11. Kaplan EL, Meier P. Nonparametric estima- tion from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Greenwood M. The natural duration of can- cer. Rep Public Health Med Subj 1926;33:1- 26.
13. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. John Wiley, 2002.
14. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B. 1972;34(2):187-220.
15. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) expe- rience. Blood. 2010;116(13):2224-2228.
16. Kayser S, Zucknick M, Dohner K, et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood. 2012;119(2):551-558.
17. Yanada M, Kurosawa S, Yamaguchi T, et al. Prognosis of acute myeloid leukemia harbor- ing monosomal karyotype in patients treat- ed with or without allogeneic hematopoietic cell transplantation after achieving complete remission. Haematologica. 2012;97(6):915- 918.
18. Cornelissen JJ, Breems D, van Putten WL, et al. Comparative analysis of the value of allo- geneic hematopoietic stem-cell transplanta- tion in acute myeloid leukemia with mono- somal karyotype versus other cytogenetic risk categories. J Clin Oncol. 2012;30(17): 2140-2146.
19. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
20. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N
Engl J Med. 2009;361(13):1235-1248.
21. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with spe- cific copy number alterations, monosomal karyotype, and dismal outcome. Blood.
2012;119(9):2114-2121.
22. Delfau-Larue MH, Klapper W, Berger F, et al.
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lym- phoma. Blood. 2015;126(5):604-611.
23. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor ver- sus no-donor analysis of myeloablative HLA-identical sibling stem cell transplanta- tion in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9): 3658-3666.
24. Fang M, Storer B, Estey E, et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood. 2011;118(6):1490-1494.
25. Poire X, Labopin M, Cornelissen JJ, et al. Outcome of conditioning intensity in acute myeloid leukemia with monosomal kary- otype in patients over 45 year-old: a study from the Acute Leukemia Working Party (ALWP) of the European Group of Blood and Marrow Transplantation (EBMT). Am J Hematol. 2015;90(8):719-724.
26. Baron F, Labopin M, Niederwieser D, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012;26(12):2462-2468.
27. Lubbert M, Suciu S, Hagemeijer A, et al. Decitabine improves progression-free sur- vival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Ann Hematol. 2016;95(2):191-199.
28. Fransolet G, Ehx G, Somja J, et al. Azacytidine mitigates experimental sclero- dermic chronic graft-versus-host disease. J Hematol Oncol. 2016;9(1):53.
haematologica | 2019; 104(6)
1175